News August 15, 2024 In the coming months, the first project ‘G2 Solutions’ will start under the leadership of Prof. Dr. Ir. Floris Foijer within the PharmaNL Shared Development Infrastructure program line. Projects within this program focus on establishing infrastructure provisions for groundbreaking pharmaceutical products and technologies for drug development.
Objective of the Funding Round
The PharmaNL Shared Development Infrastructure call 2023-1 is the first funding round within the PharmaNL Shared Development Infrastructure (SDI) program line. This program line aims to set up advanced infrastructures (such as laboratory equipment) for shared use by pharmaceutical start-ups, scale-ups, and academic research groups. Establishing such infrastructure is crucial for strengthening the pharmaceutical value chain because currently required R&D facilities and services are either not available or insufficiently developed and do not emerge through regular market mechanisms.
The projects will contribute to the expansion and strengthening of pharmaceutical hubs, knowledge institutions, and enterprises with future-proof equipment. This will lead to more efficient and effective development of new medicines and production technologies, shorter lead times, and lower costs in the pharmaceutical sector.
Approved Project
G2 Solutions, led by Prof. Dr. Ir. Floris Foijer, in collaboration with UMCG, GenomeScan, LIFE Cooperative, and Pivot Park Screening Centre
Many medicines are not equally effective in all patients, and many patients develop resistance to medications, especially in the treatment of chronic or complex diseases such as cancer. New technological developments make it possible to better map and simulate diseases in the lab. This type of technology is essential for better drug development. G2 Solutions utilizes this technology to precisely map diseases and build patient-specific models. This is combined to establish infrastructure for drug development. The infrastructure will be made available to Dutch pharmaceutical and academic partners. Additionally, G2 Solutions will use the infrastructure to collaborate with Pivot Park Screening Centre to discover new drugs. The University Medical Center Groningen will provide staff, equipment, and laboratory space for this purpose, while GenomeScan, LIFE Cooperative, and Pivot Park Screening Centre will help market the services (inter)nationally.
More Information
For more information about the Shared Development Infrastructure program line, visit the PharmaNL page. Also, read more on the ZonMw website, which implements the PharmaNL program lines.